Radioiodine for thyroid cancer: sometimes, less is best

Radioiodine for thyroid cancer: sometimes, less is best

Bibliographic Details
Main Author:	Rosalia do Prado Padovani
Format:	Article
Language:	English
Published:	Brazilian Society of Endocrinology and Metabolism
Series:	Archives of Endocrinology and Metabolism
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000100002&lng=en&tlng=en

Similar Items

Radioiodine and thyroid gland
by: Takavar A
Published: (1994-05-01)

Sometimes less is more: experience with endoscopic myringoplasty
by: Mubeen Ali, et al.
Published: (2024-03-01)

Sometimes More Is Better, and Sometimes Less Is Better: Task Complexity Moderates the Response Time Accuracy Correlation
by: Nicolas Becker, et al.
Published: (2016-08-01)

Sometimes less is more in multiple sclerosis drug switching
by: Bruna Klein da Costa, et al.
Published: (2016-08-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
by: Petra Petranović Ovčariček, et al.
Published: (2023-08-01)

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer
by: Massimiliano Pacilio, et al.
Published: (2022-07-01)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
by: Costanza Chiapponi, et al.
Published: (2021-12-01)

APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
by: K.A. GARIPOV, et al.
Published: (2020-06-01)

A practical approach on radioprotection in the treatment of radioiodine for thyroid cancer
by: Janaína Dutra Silvestre Mendes, et al.
Published: (2018-09-01)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
by: Yu-qing Sun, et al.
Published: (2022-11-01)

Interdisciplinary databank in oncoendocrinology: radioiodine refractory differentiated thyroid cancer
by: Pavel O. Rumyantsev, et al.
Published: (2022-04-01)

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: TENG Lisong, et al.
Published: (2023-05-01)

Sometimes Less Is Not Enough: A Commentary on Greiff et al. (2015)
by: André Kretzschmar
Published: (2017-01-01)

Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia
by: Ivan I. Dedov, et al.
Published: (2018-12-01)

Factors influencing successful radioiodine therapy of thyroid
by: Popadić Silvija M., et al.
Published: (2003-01-01)

Identification of thyroid gland activity in radioiodine therapy
by: Ladislav Jirsa, et al.
Published: (2017-01-01)

Direct Oral Anticoagulants Versus Vitamin K Antagonist in Elderly Patients With Atrial Fibrillation: Sometimes Less Is More, but Sometimes More Is More
by: Arthur Allen, et al.
Published: (2023-11-01)

The Effect of Radioiodine Therapy on the Prognosis of Differentiated Thyroid Cancer with Lung Metastases
by: Shenghong Zhang, et al.
Published: (2024-02-01)

Value of follow-up diagnostic radioiodine scans in differentiated thyroid cancer
by: Teresa Kraus, et al.
Published: (2024-04-01)

Redox parameters in blood of thyroid cancer patients after the radioiodine ablation
by: Spasojević-Tišma Vera D., et al.
Published: (2017-01-01)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
by: June-Key Chung, et al.
Published: (2014-09-01)

Salivary gland function in thyroid cancer patients with radioiodine administration history
by: Eva Krcalova, et al.
Published: (2020-09-01)

Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Progress in Re-differentiating Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: ZHANG Yaqi, et al.
Published: (2022-10-01)

Laughter isn’t always the best medicine, sometimes it’s one of the symptoms
by: Ioana Patricia Bacus, et al.
Published: (2023-01-01)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
by: Genpeng Li, et al.
Published: (2018-11-01)

Making sense of science: Sometimes plagiarized, sometimes not!
by: Ashish Sham Nichani
Published: (2015-01-01)

Performance tests of a portable thyroid radioiodine meter
by: Zeshu Li, et al.
Published: (2024-03-01)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
by: Wei Du, et al.
Published: (2022-02-01)

Assessment Of Radioiodine Clearance In Differentiated Thyroid Cancer Patients In Hospital Kuala Lumpur
by: Rosdi, Abdullah Hanif
Published: (2018)

Strongly Radioiodine-Positive Pancreatic Adenocarcinoma Mimicking Metastasis of Differentiated Thyroid Cancer
by: Florian Rosar, et al.
Published: (2022-08-01)

Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer
by: Yoon Ju Choi, et al.
Published: (2021-01-01)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
by: Tiziana Feola, et al.
Published: (2021-07-01)

<i>Faecalibacterium prausnitzii</i> in Differentiated Thyroid Cancer Patients Treated with Radioiodine
by: Ana Fernandes, et al.
Published: (2023-06-01)

Whole-Body Radioiodine Effective Half-Life in Patients with Differentiated Thyroid Cancer
by: Michele Klain, et al.
Published: (2021-09-01)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
by: Chao Meng, et al.
Published: (2023-02-01)

In Silico Screening and Validation of PDGFRA Inhibitors Enhancing Radioiodine Sensitivity in Thyroid Cancer
by: Xuefei Yu, et al.
Published: (2022-05-01)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022-06-01)